CCL20

Across TCGA pan-cancer cohorts, CCL20 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CCL20 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CCL20 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CCL20 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD and PDAC are the cancer types where CCL20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.302	0.861	<.001	30	view →
PDAC	OS	Quartile	All	1.000	0.707	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CCL20–LUAD (OS)

Open the LUAD breakdown →